MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
2.880
-0.180
-5.88%
After Hours: 2.950 +0.07 +2.43% 19:58 07/11 EDT
OPEN
3.060
PREV CLOSE
3.060
HIGH
3.090
LOW
2.800
VOLUME
2.25M
TURNOVER
--
52 WEEK HIGH
6.05
52 WEEK LOW
0.9101
MARKET CAP
241.09M
P/E (TTM)
-0.9472
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EDIT last week (0630-0704)?
Weekly Report · 5d ago
Weekly Report: what happened at EDIT last week (0623-0627)?
Weekly Report · 06/30 09:11
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
The Motley Fool · 06/28 09:04
2 Beaten-Down Stocks to Avoid
The Motley Fool · 06/27 12:15
Weekly Report: what happened at EDIT last week (0616-0620)?
Weekly Report · 06/23 09:10
Gene editors steady despite latest leadership shake-up at FDA
Seeking Alpha · 06/20 12:39
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Benzinga · 06/18 17:59
JonesTrading Sticks to Their Hold Rating for Editas Medicine (EDIT)
TipRanks · 06/17 14:45
More
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.